Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.
about
Interventions for fatigue in Parkinson's diseaseSide effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacologyEmerging approaches in Parkinson's disease - adjunctive role of safinamideRepurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's diseaseTargeting chelatable iron as a therapeutic modality in Parkinson's disease.A pivotal role of FOS-mediated BECN1/Beclin 1 upregulation in dopamine D2 and D3 receptor agonist-induced autophagy activation.Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.Therapeutic prospects for Parkinson disease.Dopamine receptor agonists for Parkinson's disease.Movement disorders in 2013: diagnosing and treating PD-the earlier the better?Novel thiazole derivatives: a patent review (2008 - 2012. Part 2).Early versus delayed initiation of pharmacotherapy in Parkinson's disease.Assessment of disease progression and functional benefit in neurodegenerative disease: can we tell the difference?Safinamide for the treatment of Parkinson's disease.Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.Rational drug discovery design approaches for treating Parkinson's disease.Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.Modern treatment in Parkinson's disease, a personal approach.Advances in clinical trials for movement disorders.Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.Therapeutic approaches in Parkinson's disease and related disorders.New and emerging medical therapies in Parkinson's disease.Comparison of the Performances of (18)F-FP-CIT Brain PET/MR and Simultaneous PET/CT: a Preliminary Study.The entangled ER-mitochondrial axis as a potential therapeutic strategy in neurodegeneration: A tangled duo unchained.Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.Current and experimental treatments of Parkinson disease: A guide for neuroscientists.The MPTP Story.Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patientsDo we need a new levodopa?Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.Pharmacotherapy and generic health-related quality of life in Parkinson's disease.Drp1/Fis1 interaction mediates mitochondrial dysfunction, bioenergetic failure and cognitive decline in Alzheimer's disease.ABCB1: is there a role in the drug treatment of Parkinson's disease?Statistical Models of Parkinson's Disease Progression: Predictive Validity in a 3-Year Follow-up.Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.Parkinson's disease: recent advances.Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease
P2860
Q24186581-2F752E4F-67A2-441E-82BE-034E1C5E1ED5Q26738349-32E7554C-1751-4756-A8C3-CDB4DA12E576Q26740905-89590F5F-869C-4C5F-BF04-0AC59D34B3A8Q26748711-54234281-CE3F-4355-BF48-7C362A2CB04AQ33768106-712D4F6C-8436-4FB2-878D-FE1797890912Q36777200-7A0551CA-41C6-4BBA-8C16-161B5616B224Q36925905-D7D17BC3-8F1C-4A17-B456-FDE2948058F5Q37506492-8D5664E4-B339-4B86-BA6D-3906192DC0A8Q38137889-8109F97E-74FE-4CCC-A632-6C890E3EF71AQ38169202-8F7757E0-165B-478F-AF7C-4669ED58F0AFQ38176182-8B88050C-913A-425C-84CD-6454BBC0E541Q38205485-96CC1001-B089-44AC-BF65-85BEA4123D06Q38206403-6B3563FA-2105-41A1-94E3-80C13E916334Q38219475-2E80B3C0-F57A-4334-9AD3-B48DD70FF778Q38258514-2D977604-56BA-40F5-B39F-ED0BD015FDBDQ38314257-6B69BCED-72C9-406A-BA28-C034A7148D58Q38520864-52207F04-5C46-490B-B6E0-64942B30B1A4Q38545359-138A3F34-3680-4C67-85E2-46F9F051C656Q38570529-009DD673-24FF-493B-8465-357CB804C949Q38573937-42890F80-8445-445B-AE09-CA03959BFDE6Q38656262-21744047-4653-4D22-9D6A-AD48C26EBB6DQ38687026-58DEE539-C530-487E-A075-CF04AD6C5792Q38691406-BAA4F571-AA83-4ADE-A809-0ECBF673932BQ38718194-6793B577-B36B-4AD7-AE87-BA4C6A9184BDQ38829876-985AC4C1-EABE-4142-99F5-4B3C519967E3Q38841508-778515FD-4CC8-4188-8FBA-5940CFBAE098Q38865983-B971F372-0AA6-4787-B8EA-65A8A0091DF0Q38941557-5BB25178-B9D0-4FC3-BBCA-8D5C1E3CA707Q41825283-17FC79BB-356A-4E1C-B0EB-0AFFCF2101AEQ42035690-F61BBE20-4F02-465E-85E9-822790B8CEDDQ42043001-98529C26-F71E-4D7D-A7F5-0DE88A5C0896Q46354756-B548C3DF-41BA-4F5A-BADF-C9994A75EC69Q47914989-CA829CAC-2916-4DD6-B3CD-89F16148BFFCQ49787603-F16F3E07-32E3-406E-BEF9-4E65642A3C0CQ49968346-ECACD671-6055-4C26-918D-6CFFD8571703Q50241406-98A4E43E-E11F-4624-A7AF-2C5C4E1C3A35Q52880488-3DDDBE94-C5EC-4B10-AEAD-BD81D57DED1FQ53585290-69B8E369-ABD6-4896-A83F-B8C02D0DCC3EQ58706409-50D72910-E5DE-4A0A-8651-CE3C8017211E
P2860
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pramipexole in patients with e ...... andomised delayed-start trial.
@en
Pramipexole in patients with early Parkinson's disease
@nl
type
label
Pramipexole in patients with e ...... andomised delayed-start trial.
@en
Pramipexole in patients with early Parkinson's disease
@nl
prefLabel
Pramipexole in patients with e ...... andomised delayed-start trial.
@en
Pramipexole in patients with early Parkinson's disease
@nl
P2093
P2860
P50
P1433
P1476
Pramipexole in patients with e ...... andomised delayed-start trial.
@en
P2093
Cynthia L Comella
Daniel H Massey
Helen H Hsu
Kenneth Marek
Michael P McDermott
Stefan Albrecht
P2860
P304
P356
10.1016/S1474-4422(13)70117-0
P577
2013-05-31T00:00:00Z